290 related articles for article (PubMed ID: 26004931)
1. Thrombolytic and Antiplatelet Effects of a Novel Plasminogen Activator from the Venom of Gloydius Brevicaudus Viper.
Zhang Z; Lin L; Zhang J; Zhang Q; Zhao N; Wu L; Chen J; Wu Z; Wu G; Lin J; Chen Y; Xu Y
J Atheroscler Thromb; 2015; 22(10):1080-90. PubMed ID: 26004931
[TBL] [Abstract][Full Text] [Related]
2. Expression, purification and characterization of recombinant plasminogen activator from Gloydius brevicaudus venom in Escherichia coli.
Zhang J; Meng W; Wang C; Wu Z; Wu G; Xu Y
Protein Expr Purif; 2013 Sep; 91(1):85-90. PubMed ID: 23891573
[TBL] [Abstract][Full Text] [Related]
3. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Mousa SA; Forsythe MS; Diemer M; Bozarth JM; Reilly TM
Coron Artery Dis; 1994 Nov; 5(11):919-27. PubMed ID: 7719524
[TBL] [Abstract][Full Text] [Related]
5. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of nitric oxide production contributes to the antiplatelet and antithrombotic effect of new peptide pENW (pGlu-Asn-Trp).
Liu Y; Luo W; Yang H; Fang W; Xi T; Li Y; Xiong J
Thromb Res; 2015 Aug; 136(2):319-27. PubMed ID: 26028472
[TBL] [Abstract][Full Text] [Related]
8. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo.
Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O
Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488
[TBL] [Abstract][Full Text] [Related]
9. Potent Thrombolytic Effect of
Martinez de Lizarrondo S; Gakuba C; Herbig BA; Repessé Y; Ali C; Denis CV; Lenting PJ; Touzé E; Diamond SL; Vivien D; Gauberti M
Circulation; 2017 Aug; 136(7):646-660. PubMed ID: 28487393
[TBL] [Abstract][Full Text] [Related]
10. Effect of traditional Uyghur medicine abnormal Savda Munziq extract on rabbit platelet aggregation in vitro and rat arteriovenous shunt thrombosis in vivo.
Umar A; Yimin W; Tohti I; Upur H; Berké B; Moore N
J Ethnopharmacol; 2015 Jan; 159():184-8. PubMed ID: 25449463
[TBL] [Abstract][Full Text] [Related]
11. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet aggregation and endothelial protection of I4, a new synthetic anti-diabetes sulfonylurea compound.
Ma L; Lu N; Wu G
Platelets; 2015; 26(4):342-8. PubMed ID: 24832568
[TBL] [Abstract][Full Text] [Related]
13. A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits.
Roussa VD; Stathopoulou EM; Papamichael ND; Englezopoulos CV; Rousouli KI; Trypou P; Moussis V; Tellis CC; Katsouras CS; Tsikaris V; Tselepis AD; Michalis LK
Platelets; 2011; 22(5):361-70. PubMed ID: 21158497
[TBL] [Abstract][Full Text] [Related]
14. The pyrrolidinoindoline alkaloid Psm2 inhibits platelet aggregation and thrombus formation by affecting PI3K/Akt signaling.
Su XL; Su W; Wang Y; Wang YH; Ming X; Kong Y
Acta Pharmacol Sin; 2016 Sep; 37(9):1208-17. PubMed ID: 27424653
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet activity of obovatol, a biphenolic component of Magnolia Obovata, in rat arterial thrombosis and rabbit platelet aggregation.
Park ES; Lim Y; Lee SH; Kwon BM; Yoo HS; Hong JT; Yun YP
J Atheroscler Thromb; 2011; 18(8):659-69. PubMed ID: 21512279
[TBL] [Abstract][Full Text] [Related]
16. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
[TBL] [Abstract][Full Text] [Related]
18. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
Hoffmann P; Bernat A; Savi P; Herbert JM
J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).
Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L
J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic and antiplatelet activities of Korean red ginseng extract.
Jin YR; Yu JY; Lee JJ; You SH; Chung JH; Noh JY; Im JH; Han XH; Kim TJ; Shin KS; Wee JJ; Yun YP
Basic Clin Pharmacol Toxicol; 2007 Mar; 100(3):170-5. PubMed ID: 17309520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
